Table 4.
Summary of responses of diabetic subjects to Tregitopes in vitro. Effects of Tregitopes on ELISpot responses to the panel GAD65 epitopes, as reported in detail in Table 3, are summarized here. In the two-step T cell assays, IFNγ ELISpot responses to GAD65 peptides were suppressed for 78% of the peptides tested using diabetic subject PBMC and for 74% of the peptides tested using normal control subjects. The suppression reached statistical significance for more than a quarter (26%) of all assays performed.
| Subject ID | Number of peptides tested in ELISpot | Responses suppressed by Tregitopes | Responses suppressed significantly (P < 0.05) |
|---|---|---|---|
| D1100H | 9 | 6 (67%) | 2 (22%) |
| D1101H | 14 | 12 (86%) | 4 (29%) |
| D1104H | 14 | 11 (79%) | 3 (21%) |
| D1105H | 11 | 8 (73%) | 4 (36%) |
| D1106H | 12 | 8 (67%) | 2 (17%) |
| D1107H | 7 | 7 (100%) | 3 (43%) |
|
| |||
| N668C | 10 | 9 (90%) | 4 (40%) |
| N669C | 11 | 10 (91%) | 3 (27%) |
| N670C | 11 | 11 (100%) | 4 (36%) |
| N672C | 8 | 1 (13%) | 0 (0%) |
| N674C | 14 | 9 (64%) | 3 (21%) |